5 news items
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
GUTS
20 May 24
results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
GUTS
13 May 24
or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
GUTS
13 May 24
and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
GUTS
30 Apr 24
cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
GUTS
1 Apr 24
that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements
- Prev
- 1
- Next